Physician profile
Michael D Zerafa
NPI 1437400579
$3,097.33
in general payments reported to CMS, 2019-2025
35 companies · $304 in 2025
The $304 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,337 · 2020: $398 · 2021: $655 · 2022: $253 · 2023: $127 · 2024: $23.52 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $454.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $792.80 | 2019 | |
| Novo Nordisk INC | $379.34 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $288.30 | 2021-2025 | Vraylar |
| Pfizer INC. | $205.40 | 2019-2025 | |
| Astellas Pharma US INC | $165.28 | 2019-2023 | Veozah |
| Glaxosmithkline, LLC. | $128.69 | 2019-2022 | |
| Allergan, INC. | $111.03 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $102.23 | 2020-2021 | |
| Astrazeneca Pharmaceuticals Lp | $86.24 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $75.17 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $73.29 | 2019-2021 | |
| Lilly USA, LLC | $73.05 | 2019-2025 | Zepbound, Mounjaro |
| Cardiovascular Systems INC. | $67.97 | 2021 | |
| Ironshore Pharmaceuticals INC. | $54.39 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.39 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $48.59 | 2019-2022 | |
| Cranial Technologies, INC | $46.73 | 2019-2025 | Doc Band |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.84 | 2019 | |
| Abbott Laboratories | $29.77 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $29.24 | 2019-2022 | |
| Shire North American Group INC | $26.96 | 2019 | |
| Amarin Pharma, INC. | $24.69 | 2020 | |
| Esperion Therapeutics, INC. | $23.59 | 2021 | |
| Biogen, INC. | $19.03 | 2021 | |
| Orthogenrx INC. | $18.45 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $18.35 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.85 | 2021 | |
| Dexcom, INC. | $15.77 | 2021 | |
| Amgen INC. | $14.97 | 2021 | |
| Merck Sharp & Dohme LLC | $14.88 | 2020 | |
| Grt US Holding, INC. | $13.62 | 2021 | |
| Seqirus USA INC | $13.62 | 2019 | |
| Horizon Therapeutics Plc | $13.37 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.19 | 2021 | |
| Alnylam Pharmaceuticals INC. | $12.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Zerafa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.